Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria

Next Previous
Search
Trial Profile

XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms XTEND-CIU
  • Sponsors Genentech

    • Most Recent Events

    • 25 Feb 2019 Results of post hoc analysis of XTEND-CIU analysing omalizumab treatment withdrawl after 24 and 48 weeks presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 23 May 2018 Results (n=134) assessing the impact of omalizumab on work productivity and activity impairment during double-blind period, presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 19 Mar 2018 Results assessing validity, responsiveness and change of urticaria activity and impact measure (U-AIM) by using data from this study published in the Annals of Allergy, Asthma and Immunology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top